Vertex Pharmaceuticals — full event log
Every event we have on file across every reporting year. The Data-by-year tab summarises the top 10 per year; this page shows them all.
← back to Data by year2024· 13 events
Vertex committed to reduce Scope 1 and 2 GHG emissions by 42% by 2032 using 2022 as baseline, aligned with the Science Based Targets initiative.
sustainability_report p.25
2022 and 2023 GHG Scope 1 emissions were updated in April 2025 to include emissions at the Vertex Manufacturing Center that were previously attributed to a tenant.
sustainability_report p.25
Vertex acquired Alpine Immune Sciences and its lead asset povetacicept; included $4.4B one-time acquired in-process R&D expense.
sustainability_report p.5
Set a target to gather Scope 3 data from suppliers comprising approximately 30% of total spend; data will be incorporated into 2025 reporting.
sustainability_report p.26
ERM CVS provided reasonable assurance of Fan Pier Scope 1, Scope 2 location-based, and Scope 2 market-based emissions for 2024 (in addition to limited assurance for other sites).
sustainability_report p.41
Four laboratories (1 Boston, 3 Oxford UK) received My Green Lab certifications in 2024; 7 total Vertex labs certified over past two years.
sustainability_report p.29
Undertook water risk screening for nine critical Vertex sites; identified San Diego research site as most at-risk facility due to water scarcity. Earned B- on 2024 CDP Water Security survey.
sustainability_report p.28
Vertex achieved ~98% renewable energy at its International Headquarters and research facility in the UK. Overall global energy from renewable sources reached 50% in 2024 (up from 49% in 2023). The firm invests in green energy to increase electrification and ensure long-term emissions reductions, and is targeting >90% electrification of heating/cooling systems at the new Leiden II building.
sustainability_report p.25
Vertex pursues LEED, BREEAM, SKA and Fitwel certifications across its real estate portfolio. 79% of operated square feet are green-certified in 2024. New Leiden II expansion (344,000 sq ft) targets LEED Platinum with >90% electrification of heating and cooling systems.
sustainability_report p.27
Completed comprehensive energy efficiency audit at Oxford UK research site and London HQ, identifying ~94,000 kWh of annual energy savings. Introduced a new platform across six largest R&D and manufacturing sites to monitor site-specific emissions and energy initiatives.
sustainability_report p.25
Scope 3 emissions (551,647 tCO2e in 2024) dominate Vertex's footprint. Initiated supplier emissions data collection targeting ~30% of total spend in 2024. Member of Pharmaceutical Supply Chain Initiative's Scope 3 Decarbonization Team. Introducing ESG site audits for top suppliers in high-risk countries in 2025.
sustainability_report p.26
Redesigned JOURNAVX packaging to eliminate intermediary paperboard carton. Increased CASGEVY shipper capacity from 1 to up to 4 manufactured product batches per shipper, reducing overall shipment numbers to treatment centers.
sustainability_report p.28
Diverted 130 metric tons of laboratory and manufacturing waste from landfill in 2024 through takeback programs (Tyvek gowning, gloves, Styrofoam, plastic film). Leiden I repurposed >80% of medical biowaste for second consecutive year. Green chemistry initiatives apply the 12 principles across labs.
sustainability_report p.28